Do I need to restart the titration schedule from the beginning
Sources Foundayo approval announcement Official FDA press release on orforglipron approval, April 2026 Lilly investor press release Foundayo FDA approval details, ATTAIN trial summary, pricing Wegovy pill approval release OASIS 4 trial results and Wegovy pill FDA approval, December 2025 Foundayo drug overview Clinical summary, dosing schedule, warnings, and side effect profile Foundayo vs Wegovy pill context Clinician commentary on pill vs injection tradeoffs, CNPV program Foundayo market context Lilly CEO interview, pricing strategy, patient access commentary Foundayo market analysis Analyst sales projections, manufacturing scalability, global rollout Oral semaglutide approval OASIS 4 trial data, managed care perspective on oral GLP-1 coverage ORION indirect comparison study Novo Nordisk-funded comparison of oral semaglutide vs orforglipron (OMA 2026) Foundayo US availability Launch details, LillyDirect access, retail pharmacy rollout April 2026 Medical disclaimer This article is for informational purposes only and does not constitute medical advice
Novo Nordisk, which according to its website has 77,000 employees, cut its full-year sales and profit forecasts last week, wiping $95bn off its market value since
For people who benefit from regular medical oversight, dose adjustment conversations, and built-in accountability, this structure may be valuable
Severe, persistent upper abdominal pain radiating to the back, worsening after eating, accompanied by nausea, vomiting, and fever are key warning signs requiring immediate medication discontinuation and emergency evaluation
[4] For most patients, mild ketosis during weight loss is not concerning and may even be viewed as a marker of metabolic adaptation
